BCAL Diagnostics (ASX:BDX) Interest Coverage: 0 (At Loss) (As of Dec. 2025)


What is BCAL Diagnostics Interest Coverage?

BCAL Diagnostics ASX:BDX -3.70% Interest Coverage is 0 (At Loss) as of Dec. 2025. The stock has 3 warning signs investors should review. Among 95 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 1052630.53% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. BCAL Diagnostics's Operating Income for the six months ended in Dec. 2025 was A$-5.02 Mil. BCAL Diagnostics's Interest Expense for the six months ended in Dec. 2025 was A$-0.11 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for BCAL Diagnostics's Interest Coverage or its related term are showing as below:


ASX:BDX's Interest Coverage is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 9.05
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BCAL Diagnostics  (ASX:BDX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

BCAL Diagnostics Interest Coverage Related Terms

BCAL Diagnostics Interest Coverage Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

BCAL Diagnostics Interest Coverage Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Interest Coverage
No Debt 0.00 0.00 0.00

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:BDX vs TMO, DHR, IDXX: Interest Coverage Comparison

For the Diagnostics & Research subindustry, BCAL Diagnostics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics Interest Coverage vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Interest Coverage falls into.


BCAL Diagnostics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BCAL Diagnostics's Interest Coverage for the fiscal year that ended in Jun. 2025 is calculated as

Here, for the fiscal year that ended in Jun. 2025, BCAL Diagnostics's Interest Expense was A$-0.05 Mil. Its Operating Income was A$-9.96 Mil. And its Long-Term Debt & Capital Lease Obligation was A$0.58 Mil.

BCAL Diagnostics did not have earnings to cover the interest expense.

BCAL Diagnostics's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Here, for the six months ended in Dec. 2025, BCAL Diagnostics's Interest Expense was A$-0.11 Mil. Its Operating Income was A$-5.02 Mil. And its Long-Term Debt & Capital Lease Obligation was A$2.98 Mil.

BCAL Diagnostics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
BCAL Diagnostics (ASX:BDX) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BCAL Diagnostics and its competitors. According to the industry distribution chart, BCAL Diagnostics ranks #999999 out of 95 companies in the Medical Diagnostics & Research industry.
Is BCAL Diagnostics' Interest Coverage too high?
BCAL Diagnostics' current Interest Coverage is 0 (At Loss). Based on the distribution chart, BCAL Diagnostics ranks #999999 out of 95 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does BCAL Diagnostics' Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #999999 out of 95 companies for Interest Coverage. This places BCAL Diagnostics in the lower half of its industry. The industry median Interest Coverage is 9.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BCAL Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.